S
Simon D. J. Gibbs
Researcher at Monash University
Publications - 58
Citations - 3174
Simon D. J. Gibbs is an academic researcher from Monash University. The author has contributed to research in topics: AL amyloidosis & Amyloidosis. The author has an hindex of 18, co-authored 58 publications receiving 2684 citations. Previous affiliations of Simon D. J. Gibbs include Box Hill Hospital & University College London.
Papers
More filters
Journal ArticleDOI
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery
Don Poldermans,Jeroen J. Bax,Eric Boersma,Stefan De Hert,Erik Eeckhout,Gerry Fowkes,Bulent Gorenek,Michael G. Hennerici,Bernard Iung,Malte Kelm,Keld Kjeldsen,Steen Dalby Kristensen,Jose Lopez-Sendon,Paolo Pelosi,François Philippe,Luc Pierard,Piotr Ponikowski,Jean-Paul Schmid,Olav F.M. Sellevold,Rosa Sicari,Greet Van den Berghe,Frank Vermassen,Sanne E. Hoeks,Ilse Vanhorebeek,Alec Vahanian,Angelo Auricchio,Claudio Ceconi,Veronica Dean,Gerasimos Filippatos,Christian Funck-Brentano,Richard J. Hobbs,Peter Kearney,Theresa McDonagh,Keith McGregor,Bogdan A. Popescu,Zeljko Reiner,Udo Sechtem,Per Anton Sirnes,Michal Tendera,Panos E. Vardas,Petr Widimsky,Raffaele De Caterina,Stefan Agewall,Nawwar Al Attar,Felicita Andreotti,Stefan D. Anker,Gonzalo Barón-Esquivias,Guy Berkenboom,Laurent Chapoutot,Renata Cifkova,Pompilio Faggiano,Simon D. J. Gibbs,Henrik Steen Hansen,Laurence Iserin,Carsten W. Israel,Ran Kornowski,Nekane Murga Eizagaechevarria,Mauro Pepi,Massimo F Piepoli,Hans-Joachim Priebe,Martin Scherer,Janina Stępińska,David P. Taggart,Marco Tubaro +63 more
TL;DR: The current joint position is that the initiation of beta blockers in patients who will undergo non-cardiac surgery should not be considered routine, but should be considered carefully by each patient's treating physician on a case-by-case basis.
Journal ArticleDOI
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.
Nelson Leung,Frank Bridoux,Vecihi Batuman,Aristeidis Chaidos,Paul Cockwell,Vivette D. D'Agati,Angela Dispenzieri,Fernando C. Fervenza,Jean Paul Fermand,Simon D. J. Gibbs,Julian D. Gillmore,Guillermo A. Herrera,Arnaud Jaccard,Dragan Jevremovic,Efstathios Kastritis,Vishal Kukreti,Robert A. Kyle,Helen J. Lachmann,Christopher P. Larsen,Heinz Ludwig,Glen S. Markowitz,Giampaolo Merlini,Peter Mollee,Maria M. Picken,Vincent Rajkumar,Virginie Royal,Paul W. Sanders,Sanjeev Sethi,Christopher P. Venner,Peter M. Voorhees,Ashutosh D. Wechalekar,Brendan M. Weiss,Samih H. Nasr +32 more
TL;DR: The IKMG redefines MGRS as a clonal proliferative disorder that produces a nephrotoxic monoclonal immunoglobulin and does not meet previously defined haematological criteria for treatment of a specific malignancy.
Journal ArticleDOI
Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome
Jennifer H. Pinney,Carol J. Whelan,Aviva Petrie,Jason Dungu,Jason Dungu,Sanjay M Banypersad,Sanjay M Banypersad,Prayman T. Sattianayagam,Ashutosh D. Wechalekar,Simon D. J. Gibbs,Christopher P. Venner,Nancy Wassef,Carolyn A. McCarthy,Janet A. Gilbertson,Dorota Rowczenio,Philip N. Hawkins,Julian D. Gillmore,Helen J. Lachmann +17 more
TL;DR: Factors at baseline associated with a worse outcome in ATTRwt are positive troponin T, a pacemaker, and NYHA class IV symptoms, and the age of the patient at diagnosis and NT pro‐BNP level can aid in distinguishing AT TRwt from AL amyloidosis.
Journal ArticleDOI
Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study.
Sanjay M Banypersad,Daniel Sado,Andrew S. Flett,Simon D. J. Gibbs,Jennifer H. Pinney,Viviana Maestrini,Andrew T Cox,Marianna Fontana,Carol J. Whelan,Ashutosh D. Wechalekar,Philip N. Hawkins,James C. Moon +11 more
TL;DR: In this article, the authors used equilibrium contrast cardiovascular magnetic resonance (EQ-CMR) to quantify the cardiac interstitial compartment, measured as myocardial extracellular volume (ECV) fraction, hypothesizing it would reflect amyloid burden.
Journal ArticleDOI
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
Christopher P. Venner,Thirusha Lane,Darren Foard,Lisa Rannigan,Simon D. J. Gibbs,Jennifer H. Pinney,Carol J. Whelan,Helen J. Lachmann,Julian D. Gillmore,Philip N. Hawkins,Ashutosh D. Wechalekar +10 more
TL;DR: CVD is a highly effective regimen producing durable responses in AL amyloidosis; the deep clonal responses may overcome poor prognosis in advanced-stage disease.